Which conditions does the VA (Veterans Affairs) and Medicare reimburse for ketamine (or esketamine) therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

VA and Medicare Reimbursement for Ketamine/Esketamine

The VA reimburses ketamine infusion and intranasal esketamine for treatment-resistant depression (TRD) after failure of at least 2 adequate antidepressant trials, and for acute suicidal ideation in major depressive disorder (MDD); Medicare covers FDA-approved intranasal esketamine (Spravato) for these same indications, but does NOT routinely cover off-label IV ketamine infusion.

VA-Covered Diagnoses

Based on the 2022 VA/DoD Clinical Practice Guidelines, the VA provides reimbursement for:

1. Treatment-Resistant Depression (TRD)

  • Specific criteria: Patients with MDD who have failed at least 2 adequate trials of antidepressant medications 1
  • Both ketamine infusion and esketamine are covered as treatment options 1
  • Must be used either as monotherapy or in conjunction with an ongoing oral antidepressant 1
  • Not approved as first-line treatment—reserved specifically for patients where previous therapies have failed or were not tolerated 1

2. Major Depressive Disorder with Acute Suicidal Ideation or Behavior

  • Ketamine infusion is supported as adjunctive treatment for short-term reduction in suicidal ideation 2, 1
  • Must be used in conjunction with an oral antidepressant 2
  • The 2024 VA/DoD suicide prevention guideline specifically endorses this indication 2

3. Schizophrenia with Suicide Risk

  • The 2024 guidelines mention pharmacologic treatments including ketamine infusion for suicide risk management in patients with schizophrenia 2

Medicare Coverage

Medicare Part D and traditional Medicare coverage differs significantly:

Covered:

  • Intranasal esketamine (Spravato) for FDA-approved indications 3:
    • Treatment-resistant depression in adults (as monotherapy or with oral antidepressant)
    • Depressive symptoms in adults with MDD and acute suicidal ideation or behavior (with oral antidepressant)

NOT Typically Covered:

  • Off-label IV ketamine infusion is generally not reimbursed by Medicare, as it lacks FDA approval for depression
  • Patients seeking IV ketamine typically pay out-of-pocket or use VA benefits if eligible

Critical Implementation Requirements

For Esketamine (Both VA and Medicare):

  • REMS program participation required 3
  • Mandatory 2-hour post-administration monitoring 1, 3
  • Healthcare setting and pharmacy must be certified 1
  • Blood pressure assessment before and after administration 3

Treatment Duration Expectations:

  • TRD: Therapeutic benefit should be evaluated at end of 4-week induction phase to determine continuation 3
  • Acute suicidal ideation: Evidence of benefit evaluated after 4 weeks; treatment beyond 4 weeks has not been systematically evaluated 3

Important Caveats

Contraindications that would prevent reimbursement 3:

  • Aneurysmal vascular disease (aortic, intracranial, peripheral arterial)
  • Arteriovenous malformation
  • Intracerebral hemorrhage
  • Hypersensitivity to ketamine or esketamine

Documentation requirements for approval:

  • Must document failure of at least 2 adequate antidepressant trials for TRD 1
  • For suicide risk: documented acute suicidal ideation or behavior with MDD diagnosis 2
  • Ongoing oral antidepressant therapy (required for esketamine approval) 1, 3

Key limitation: The effectiveness of esketamine in preventing suicide or reducing suicidal ideation/behavior has NOT been established, despite its approval for this indication 1, 3. This represents an evidence-practice gap that clinicians should discuss with patients.

The VA system offers broader access to both ketamine formulations compared to Medicare, which strictly limits coverage to the FDA-approved intranasal esketamine product with its associated REMS requirements.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.